前列地尔合并肾康片对2型糖尿病肾病患者血清TNF-α、IL-6及IL-8水平的影响

Effects of alprostadil combined with Shenkang tablet on serum TNF-α,IL-6 and IL-8 levels in patients with type 2 diabetic nephropathy

目的研究前列地尔合并肾康片对2型糖尿病肾病患者血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)及白介素-8(IL-8)水平的影响。方法选取2014年6月~2015年5月我院收治的62例2型糖尿病肾病患者,根据随机抽签法分为试验组与对照组,各31例。对照组使用20 m L的生理盐水和10μg的前列地尔混合后,静脉推注的方式给药,1次/d。试验组在对照组治疗的基础上口服肾炎康复片,一次5片,一天3次。所有患者的治疗疗程均为4周。观察治疗前和治疗4周后的空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、TNF-α、IL-6及IL-8水平变化,评判两组患者的不良反应。结果治疗后,试验组的TNF-α、IL-6及IL-8水平显著低于对照组[(7.30±0.41)ng/L vs(9.44±1.78)ng/L,(9.39±0.31)ng/L vs(11.36±0.66)ng/L,(7.25±0.95)ng/L vs(11.35±1.07)ng/L](P<0.05)。试验组的FBG、Hb A1c水平显著低于对照组[(6.52±0.40)mmol/L vs(9.32±0.64)mmol/L,(6.53±0.60)%vs(7.44±0.68)%](P<0.05)。试验组和对照组的不良反应率比较差异无统计学意义[12.90%(4/31)vs 16.13%(5/31)](P>0.05)。结论前列地尔合并肾康片能明显降低2型糖尿病肾病患者血清TNF-α、IL-6、IL-8、FBG、Hb A1c水平,临床疗效良好,安全性高。

Objective To explore the effects of alprostadil combined with Shenkang tablet on serum TNF-α, IL-6 and IL-8 levels in patients with type 2 diabetic nephropathy. Methods Sixty-two patients with type 2 diabetic nephropathy in our hospital from June 2014 to May 2015 were enrolled in the study. According to the randomized method, the patients were divided into experimental group（n=31） and control group（n=31）. The control group was treated with 20 mL of physiological saline and 10 μg of alprostadil intravenously once a day. The experimental group was given Shenkang tablets orally once five, three times a day based on the treatment of the control groups. All patients were treated for 4 weeks. The changes of fasting blood glucose （FBG）, glyeosylated hemoglobin（HbAlc）, TNF-α/ IL-6 and IL-8 levels before and 4 weeks after treatment were observed, and the adverse reactions of the two groups were evaluated. Results After treatment, the levels of TNF-α, IL-6 and IL-8 in the experimental group[（7.30±0.41） ng/L, （9.39±0.31）ng/L, 7.25± 0.95）ng/L] were significantly lower than those in the control group [（9.44±1.78）ng/L, （11.36±0.66） ng/L, （11.35±1.07） ng/L）] （P〈0.05）.The levels of FBG and HbA1c in the experimental group[（6.52±0.40） mmol/L, （6.53±0.60）%] were significantly lower than those in the control group[（9.32±0.64） mmol/L, （7.44±0.68）%] （P〈0.05）. There was no significant difference in the adverse reaction rate between the experimental group and the control group[12.90%（4/31） vs 16.13% （5/ 31）] （P〉0.05）. Conclusion Prostaglandil combined with Shenkang tablet can significantly reduce the levels of serum TNF-α, IL-6, IL-8, FBG and HbAlc in patients with type 2 diabetic nephropathy. The clinical efficacy is good and the safety is high.